Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04286386 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam

StatusWithdrawn
PhaseNot specified
Started2019-12-19
View on ClinicalTrials.gov ↗

Amendment history

2026-09-16
Trial status changed: Active, Not Recruiting → Withdrawn
Trial withdrawn: No Participants Enrolled
2026-04-28
Study Status v17
Primary completion pushed: 2026-04-30 → 2028-04-30
Completion pushed: 2026-04-30 → 2028-04-30
2026-04-13
7 amendments v10-v16
7 re-verifications since 2024-05-31, no change to tracked fields
2024-05-07
Study Status v9
Primary completion date2024-04-30→2026-04-30
Completion date2024-04-30→2026-04-30
2023-11-29
4 amendments v5-v8
4 re-verifications since 2023-08-24, no change to tracked fields
Show 4 earlier versions
2023-03-16
Study Status, Contacts/Locations v4
Primary completion date2023-02-28→2024-04-30
Completion date2023-02-28→2024-04-30
2022-11-16
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v3
Trial statusRecruiting→Active, Not Recruiting
Study sitesdetails revised at 1 of 1 site
2022-10-31
Study Status v2
Primary completion date2022-02-28→2023-02-28
Completion date2022-02-28→2023-02-28
2021-03-24
Study Identification, Study Status v1
Re-verified, no change to tracked fields
2020-02-24
Original filing
This trial examines if a prostate magnetic resonance spectroscopic imaging can be performed on a 3T scanner using an investigational contrast called hyperpolarized 13-C pyruvate for the development of a clinical prostate cancer exam. 3T refers to the strength of the magnetic resonance spectroscopic imaging (MRSI) machine. MRSI is a magnetic resonance imaging (MRI) technique that can show certain chemical differences in healthy and diseased prostate tumor tissue compared to standard multiparametric MRI that may not detect the tumor. Hyperpolarized (HP) 13-C pyruvate is a contrast drug that may help the scanner see the tumor site better during imaging. Hyperpolarization of 13-C pyruvate may allow pyruvate and its metabolites to be detected upon injection, which in turn, allow the prostate cancer to be found and treated.
Trial Details
NCT Number NCT04286386
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)
Conditions Prostate Adenocarcinoma
Start Date 2019-12-19
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-15